Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) has announced that it will report its third quarter 2021 financial results on November 10, 2021, after market closure. No accompanying teleconference will be held. The company specializes in precision medicine and is focused on enhancing drug discovery, particularly in targeted oncology and genetic diseases, using its proprietary Dynamo™ platform that integrates advanced computational and experimental technologies.

Positive

• Focus on precision medicine and innovative drug discovery.
• Dynamo™ platform aims to address previously intractable protein targets.

Negative

• None.

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 financial results after the close of market on Wednesday, November 10, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. Relay Therapeutics’ Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Pete Rahmer
Senior Vice President, Corporate Affairs and Investor Relations
617-322-0715
prahmer@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics report its Q3 2021 financial results?

Relay Therapeutics will report its Q3 2021 financial results on November 10, 2021.

Is there a teleconference for Relay Therapeutics' financial results?

No, Relay Therapeutics will not hold a teleconference in conjunction with its financial results.

What is Relay Therapeutics' focus in drug discovery?

Relay Therapeutics focuses on precision medicine and enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

What technology platform does Relay Therapeutics use?

Relay Therapeutics utilizes the Dynamo™ platform, which integrates computational and experimental approaches for drug discovery.